Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity

International Journal of Pharmaceutics

Volumn 377, Issue 1-2, 2009, Pages 76-84

  Zahedi, Payam ^a   De Souza, Raquel ^a   Piquette Miller, Micheline ^a   Allen, Christine ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chitosan; Docetaxel; Injectable; Intraperitoneal; Localized sustained delivery; Phospholipid

Indexed keywords

CHITOSAN; DOCETAXEL; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG STABILITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PERITONEAL CAVITY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHITOSAN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; INJECTIONS, INTRAPERITONEAL; MICE; PHOSPHOLIPIDS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649664258     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.05.003     Document Type: Article

References (68)

1. Adam R.A., and Adam Y.G. Malignant ascites: past, present, and future. J. Am. Coll. Surg. 198 (2004) 999-1011
2. Ali S.M., Hoemann M.Z., Aube J., Georg G.I., Mitscher L.A., and Jayasinghe L.R. Butitaxel analogues: synthesis and structure-activity relationships. J. Med. Chem. 40 (1997) 236-241
3. Anderson J.M. Biological responses to materials. Annu. Rev. Mater. Res. 31 (2001) 81-110
4. Angelova N., and Hunkeler D. Rationalizing the design of polymeric biomaterials. Trends Biotechnol. 17 (1999) 409-421
5. Bobrowski W.F., McDuffie J.E., Sobocinski G., Chupka J., Olle E., Bowman A., and Albassam M. Comparative methods for multiplex analysis of cytokine protein expression in plasma of lipopolysaccharide-treated mice. Cytokine 32 (2005) 194-198
6. Cho J., Grant J., Piquette-Miller M., and Allen C. Synthesis and physicochemical and dynamic mechanical properties of a water-soluble chitosan derivative as a biomaterial. Biomacromolecules 7 (2006) 3548-13548
7. Clarke S.J., and Rivory L.P. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 36 (1999) 99-114
8. Clement Y.N., and Williams A.F. Protection against paracetamol-induced hepatic injury by prazosin pre-treatment in CD-1 mice. Mutat. Res. 579 (2005) 182-188
9. Crown J., and O'Leary M. The taxanes: an update. Lancet 355 (2000) 1176-1178
10. de Bree E., Theodoropoulos P.A., Rosing H., Michalakis J., Romanos J., Beijnen J.H., and Tsiftsis D.D. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat. Rev. 32 (2006) 471-482
11. De Souza R., Zahedi P., Allen C., and Piquette-Miller M. Biocompatibility of injectable chitosan-phospholipid implant systems. Biomaterials (2009) 003 10.1016/j.biomaterials.2009.04
12. Dhanikula A.B., and Panchagnula R. Localized paclitaxel delivery. Int. J. Pharm. 183 (1999) 85-100
13. Engels F.K., Mathot R.A.A., and Verweij J. Alternative drug formulations of docetaxel: a review. Anti-Cancer Drugs 18 (2007) 95-103
14. Flessner M.F. Intraperitoneal Drug Therapy: Physical and Biological Principles (2007), Springer, New York, US
15. Freier T., Koh H.S., Kazazian K., and Shoichet M.S. Controlling cell adhesion and degradation of chitosan films by N-acetylation. Biomaterials 26 (2005) 5872-5878
16. Fukamizo T., and Brzezinski R. Chitosanase from Streptomyces sp. strain N174: a comparative review of its structure and function. Biochem. Cell. Biol. 75 (1997) 687-696
17. Fulzele S.V., Satturwar P.M., and Dorle A.K. Study of the biodegradation and in vivo biocompatibility of novel biomaterials. Eur. J. Pharm. Sci. 20 (2003) 53-61
18. Fung L.K., and Saltzman W.M. Polymeric implants for cancer chemotherapy. Adv. Drug. Deliver. Rev. 26 (1997) 209-230
19. Gligorov J., and Lotz J.P. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 (2004) 3-8
20. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53 (2002) 615-627
21. Grant J., Blicker M., Piquette-Miller M., and Allen C. Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel. J. Pharm. Sci. 94 (2005) 1512-1527
22. Grant J., Lee H., Lim Soo P., Cho J., Piquette-Miller M., and Allen C. Influence of molecular organization and interactions on drug release for an injectable polymer-lipid blend. Int. J. Pharm. 360 (2008) 83-90
23. Grant J., Tomba J.P., Lee H., and Allen C. Relationship between composition and properties for stable chitosan films containing lipid microdomains. J. Appl. Polym. Sci. 103 (2007) 3453-3460
24. Grayson A.C.R., Voskerician G., Lynn A., Anderson J.M., Cima M.J., and Langer R. Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip. J. Biomater. Sci. Polym. Ed. 15 (2004) 1281-1304
25. Hatefi A., and Amsden B. Biodegradable injectable in situ forming drug delivery systems. J. Control. Release 80 (2002) 9-28
26. Hennenfent K.L., and Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann. Oncol. 17 (2006) 735-749
27. Hickey T., Kreutzer D., Burgess D.J., and Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J. Biomed. Mater. Res. 61 (2002) 180-187
28. Hirano S., Tsuchida H., and Nagao N. N-acetylation in chitosan and the rate of its enzymic-hydrolysis. Biomaterials 10 (1989) 574-576
29. Ho E.A., Soo P.L., Allen C., and Piquette-Miller M. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J. Control. Release 117 (2007) 20-27
30. Ho E.A., Vassileva V., Allen C., and Piquette-Miller M. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. J. Control. Release 104 (2005) 181-191
31. Howell S.B. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int. J. Gynecol. Cancer 18 (2008) 20-25
32. Iversen C., Kjoniksen A.L., Nystrom B., Nakken T., Palmgren O., and Tande T. Linear and nonlinear rheological responses in aqueous systems of hydrophobically modified chitosan and its unmodified analogue. Polym. Bull. 39 (1997) 747-754
33. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13 (2005) 31-36
34. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004) 423-436
35. Lee K.Y., Ha W.S., and Park W.H. Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials 16 (1995) 1211-1216
36. Lennernas B., Albertsson P., Damber J.E., and Norrby K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. APMIS 112 (2004) 201-209
37. Lim S.H., and Hudson S.M. Synthesis and antimicrobial activity of a water-soluble chitosan derivative with a fiber-reactive group. Carbohydr. Res. 339 (2004) 313-319
38. Lim Soo P., Cho J., Grant J., Ho E., Piquette-Miller M., and Allen C. Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology. Eur. J. Pharm. Biopharm. 69 (2008) 149-157
39. Lowenthal R.M., and Eaton K. Toxicity of chemotherapy. Hematol. Oncol. Clin. North Am. 10 (1996) 967-990
40. Ma G.P., Yang D.Z., Zhou Y.S., Xiao M., Kennedy J.F., and Nie J. Preparation and characterization of water-soluble N-alkylated chitosan. Carbohydr. Polym. 74 (2008) 121-126
41. Maenpaa J.U. Docetaxel: promising and novel combinations in ovarian cancer. Brit. J. Cancer 89 (2003) S29-S34
42. Mao J.S., Liu H.F., Yin Y.J., and Yao K.D. The properties of chitosan-gelatin membranes and scaffolds modified with hyaluronic acid by different methods. Biomaterials 24 (2003) 1621-1629
43. Marchettini P., Stuart O.A., Mohamed F., Yoo D., and Sugarbaker P.H. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemoth. Pharm. 49 (2002) 499-503
44. Masubuchi Y., Suda C., and Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J. Hepatol. 42 (2005) 110-116
45. Morgan R.J., Doroshow J.H., Synold T., Lim D., Shibata S., Margolin K., Schwarz R., Leong L., Somlo G., Twardowski P., Yen Y., Chow W., Lin P., Paz B., Chu D., Frankel P., and Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res. 9 (2003) 5896-5901
46. Onishi H., and Machida Y. Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials 20 (1999) 175-182
47. Oosterling S.J., van der Bij G.J., van Egmond M., and van der Sijp J.R.M. Surgical trauma and peritoneal recurrence of colorectal carcinoma. Eur. J. Surg. Oncol. 31 (2005) 29-37
48. Packhaeuser C.B., Schnieders J., Oster C.G., and Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. 58 (2004) 445-455
49. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int. J. Pharm. 172 (1998) 1-15
50. Parveen S., and Sahoo S.K. Polymeric nanoparticles for cancer therapy. J. Drug. Target. 16 (2008) 108-123
51. Pavithra D., and Doble M. Biofilm formation, bacterial adhesion and host response on polymeric implants-issues and prevention. Biomed. Mater. 3 (2008) 1-13
52. Pillai O., and Panchagnula R. Polymers in drug delivery. Curr. Opin. Chem. Biol. 5 (2001) 447-451
53. Ramos V.M., Rodriguez N.M., Rodriguez M.S., Heras A., and Agullo E. Modified chitosan carrying phosphonic and alkyl groups. Carbohydr. Polym. 51 (2003) 425-429
54. Rinaudo M., Auzely R., Vallin C., and Mullagaliev I. Specific interactions in modified chitosan systems. Biomacromolecules 6 (2005) 2396-2407
55. Shimada T., Nomura M., Yokogawa K., Endo Y., Sasaki T., Miyamoto K., and Yonemura Y. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. J. Pharm. Pharmacol. 57 (2005) 177-181
56. Sinha V.R., and Trehan A. Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres. Drug Deliv. 12 (2005) 133-139
57. Ta H.T., Dass C.R., and Dunstan D.E. Injectable chitosan hydrogels for localised cancer therapy. J. Control. Release 126 (2008) 205-216
58. Tannock I.F., Lee C.M., Tunggal J.K., Cowan D.S.M., and Egorin M.J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. 8 (2002) 878-884
59. Tsai M., Lu Z., Wang J., Yeh T.K., Wientjes M.G., and Au J.L.S. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm. Res. 24 (2007) 1691-1701
60. Ullman-Cullere M.H., and Foltz C.J. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab. Anim. Sci. 49 (1999) 319-323
61. Urien S., Barre J., Morin C., Paccaly A., Montay G., and Tillement J.P. Docetaxel serum protein binding with high affinity to alpha(1)-acid glycoprotein. Invest. New Drugs 14 (1996) 147-151
62. van Zuylen L., Verweij J., and Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19 (2001) 125-141
63. Vassileva V., Allen C.J., and Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol. Cancer Ther. 7 (2008) 630-637
64. Vassileva V., Grant J., De Souza R., Allen C., and Piquette-Miller M. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemoth. Pharm. 60 (2007) 907-914
65. Vassileva V., Moriyama E.H., De Souza R., Grant J., Allen C.J., Wilson B.C., and Piquette-Miller M. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. Br. J. Cancer 99 (2008) 2037-2043
66. ®/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anti-Cancer Drugs 18 (2007) 283-289
67. Walley K.R., Lukacs N.W., Standiford T.J., Strieter R.M., and Kunkel S.L. Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Infect. Immun. 65 (1997) 3847-3851
68. Wang H., Xu D.X., Lv J.W., Ning H., and Wei W. Melatonin attenuates lipopolysaccharide (LPS)-induced apoptotic liver damage in d-galactosamine-sensitized mice. Toxicology 237 (2007) 49-57